Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma.

17 Interestingly, the patients with the highest quartile average and trough serum olaratumab levels, i.e., greatest exposure, showed a trend toward an improved PFS and OS. 23 An exploratory analysis of tumor PDGFRα expression did not reveal a significant relationship with PFS or OS; however, the assay was nonspecific and reanalysis of tumors with immunohistochemistry using a more specific antibody identified the expected proportion of detectable PDGFRα expression, which was well balanced between the two arms (33% patients receiving doxorubicin and olaratumab and 34% patients receiving doxorubicin).

also in 53,322 other papers